{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T19:14:52Z","timestamp":1763234092076,"version":"build-2065373602"},"reference-count":46,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objective: To determine the prevalence of positive antiphospholipid (aPL) antibodies among pregnant women with placenta-mediated complications delivered at &gt;340\/7 weeks of gestation. Methods: This was a single-center retrospective observational study conducted between 2017 and 2022. Inclusion criteria included pregnant or post-partum women, &gt;18 years, diagnosed with any of the following placenta-mediated complications and delivered at &gt;340\/7 weeks of gestation: small-for-gestational-age neonate (SGA \u2264 5th percentile according to local birthweight charts), preeclampsia with severe features, and placental abruption. The primary outcome was the prevalence of positive aPL antibodies: Lupus anticoagulant, Anticardiolipin, or Anti-\u00df2glycoprotein1. Results: Overall, 431 women met the inclusion criteria. Of them, 378(87.7%) had an SGA neonate, 30 had preeclampsia with severe features (7%), 23 had placental abruption (5.3%), and 21 patients had multiple diagnoses(4.9%). The prevalence of aPL antibodies in the cohort was 4.9% and was comparable between the three subgroups (SGA\u20143.9%; PET with severe features\u20143.3%; and placental abruption\u201413% (p = 0.17)). Conclusion: aPL antibodies prevalence in women with placenta-mediated complications &gt; 34 weeks of gestation was 4.9%, with comparable prevalence rates among the three subgroups. Future prospective studies are needed to delineate the need for treatment in those who tested positive for aPL antibodies and do not meet Anti-Phospholipid Antibody Syndrome clinical criteria.<\/jats:p>","DOI":"10.3390\/jcm12134516","type":"journal-article","created":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:41:27Z","timestamp":1688604087000},"page":"4516","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Anti-Phospholipid Antibodies in Women with Placenta-Mediated Complications Delivered at &gt;34 Weeks of Gestation"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2890-2781","authenticated-orcid":false,"given":"Uri","family":"Amikam","sequence":"first","affiliation":[{"name":"Lis Hospital for Women, Sourasky Medical Center, Tel Aviv 6423906, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7387-409X","authenticated-orcid":false,"given":"Alyssa","family":"Hochberg","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel"},{"name":"Helen Schneider Hospital for Women, Rabin Medical Center, Petach Tikva 4941492, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Shenhav","sequence":"additional","affiliation":[{"name":"Lis Hospital for Women, Sourasky Medical Center, Tel Aviv 6423906, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian","family":"Haj","sequence":"additional","affiliation":[{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarit","family":"Hochberg-Klein","sequence":"additional","affiliation":[{"name":"Palmerston North Hospital, Te Whatu Ora Health NZ, Palmerston North 4442, New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4443-388X","authenticated-orcid":false,"given":"Liran","family":"Hiersch","sequence":"additional","affiliation":[{"name":"Lis Hospital for Women, Sourasky Medical Center, Tel Aviv 6423906, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yariv","family":"Yogev","sequence":"additional","affiliation":[{"name":"Lis Hospital for Women, Sourasky Medical Center, Tel Aviv 6423906, Israel"},{"name":"Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv 6423906, Israel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.autrev.2018.12.006","article-title":"The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases","volume":"18","author":"Lefkou","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1002\/1529-0131(199907)42:7<1309::AID-ANR1>3.0.CO;2-F","article-title":"International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome: Report of an International workshop","volume":"42","author":"Wilson","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)","volume":"4","author":"Miyakis","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nrrheum.2017.124","article-title":"Diagnosing antiphospholipid syndrome: \u2018extra-criteria\u2019 manifestations and technical advances","volume":"13","author":"Sciascia","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.autrev.2014.02.003","article-title":"14th International Congress on Antiphospholipid Antibodies Task Force Report on Obstetric Antiphospholipid Syndrome","volume":"13","author":"Andrade","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1177\/096120339800700218","article-title":"Placental pathology in antiphospholipid syndrome","volume":"7","author":"Levy","year":"1998","journal-title":"Lupus"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.autrev.2015.01.008","article-title":"Histopathology in the placentae of women with antiphospholipid antibodies: A systematic review of the literature","volume":"14","author":"Viall","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"(2012). Gynecologists Practice Bulletin No. 132: Antiphospholipid syndrome. Obstet. Gynecol., 120, 1514\u20131521.","DOI":"10.1097\/01.AOG.0000423816.39542.0f"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nrrheum.2015.88","article-title":"Current treatment of antiphospholipid syndrome: Lights and shadows","volume":"11","author":"Espinosa","year":"2015","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"425","DOI":"10.3899\/jrheum.120576","article-title":"Treatment of 139 Pregnancies in Antiphospholipid-positive Women Not Fulfilling Criteria for Antiphospholipid Syndrome: A Retrospective Study","volume":"40","author":"Ruffatti","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1111\/jth.15053","article-title":"The prevalence of antiphospholipid antibodies in women with late pregnancy complications and low-risk for chromosomal abnormalities","volume":"18","author":"Foddai","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.semarthrit.2016.05.006","article-title":"Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: Prevalence and treatment efficacy in pregnancies","volume":"46","author":"Mekinian","year":"2016","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/rheumatology\/kez419","article-title":"Comparative study of obstetric antiphospholipid syndrome (OAPS) and non-criteria obstetric APS (NC-OAPS): Report of 1640 cases from the EUROAPS registry","volume":"59","author":"Lefkou","year":"2020","journal-title":"Rheumatology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1177\/0961203320954520","article-title":"16th international congress on antiphospholipid antibodies task force. Report on obstetric antiphospholipid syndrome","volume":"29","author":"Benson","year":"2020","journal-title":"Lupus"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1080\/01443610903052073","article-title":"Prevalence and significance of antiphospholipid antibodies in selected at-risk obstetrics cases: A comparative prospective study","volume":"29","author":"Saha","year":"2009","journal-title":"J. Obstet. Gynaecol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1177\/0961203318787035","article-title":"Antiphospholipid antibodies in women with severe preeclampsia and placental insufficiency: A case-control study","volume":"27","author":"Gibbins","year":"2018","journal-title":"Lupus"},{"key":"ref_17","first-page":"311","article-title":"Birth weight standards in the live-born population in Israel","volume":"7","author":"Dollberg","year":"2005","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"(2020). Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet. Gynecol., 135, e237\u2013e260.","DOI":"10.1097\/AOG.0000000000003891"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2828","DOI":"10.1111\/jth.15047","article-title":"Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: Update of the guidelines for lupus anticoagulant detection and interpretation","volume":"18","author":"Devreese","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Vandevelde, A., and Devreese, K.M.J. (2022). Laboratory Diagnosis of Antiphospholipid Syndrome: Insights and Hindrances. J. Clin. Med., 11.","DOI":"10.3390\/jcm11082164"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Alijotas-Reig, J., Esteve-Valverde, E., Anunciaci\u00f3n-Llunell, A., Marques-Soares, J., Pardos-Gea, J., and Mir\u00f3-Mur, F. (2022). Pathogenesis, Diagnosis and Management of Obstetric Antiphospholipid Syndrome: A Comprehensive Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030675"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1002\/art.1780341005","article-title":"The Prevalence of Antiphospholipid Antibodies in Women With Recurrent Spontaneous Abortion, Women With Successful Pregnancies, and Women Who Have Never Been Pregnant","volume":"34","author":"Parke","year":"1991","journal-title":"Arthritis Rheum."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0002-9378(89)90522-X","article-title":"The prevalence and biologic significance of lupus anticoagulant and antic ardiolipin antibodies in a general obstetric population","volume":"161","author":"Lockwood","year":"1989","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/AOG.0b013e3182a1060e","article-title":"Antiphospholipid Antibodies in Stillbirth","volume":"122","author":"Silver","year":"2013","journal-title":"Obstet. Gynecol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/j.1538-7836.2005.01485.x","article-title":"Lupus anticoagulants and the risk of a first episode of deep venous thrombosis","volume":"3","author":"Lutters","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1002\/acr.22066","article-title":"Estimated Frequency of Antiphospholipid Antibodies in Patients with Pregnancy Morbidity, Stroke, Myocardial Infarction, and Deep Vein Thrombosis: A Critical Review of the Literature","volume":"65","author":"Andreoli","year":"2013","journal-title":"Arthritis Care Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3389\/fendo.2019.00055","article-title":"Neonatal Morbidities of Fetal Growth Restriction: Pathophysiology and Impact","volume":"10","author":"Malhotra","year":"2019","journal-title":"Front. Endocrinol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.ajog.2009.10.889","article-title":"Defining normal and abnormal fetal growth: Promises and challenges","volume":"202","author":"Zhang","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_29","first-page":"31","article-title":"Fetal growth restriction: Current perspectives","volume":"5","author":"Faraci","year":"2011","journal-title":"J. Prenat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.ajog.2011.07.017","article-title":"Evaluation and management of severe preeclampsia before 34 weeks\u2019 gestation","volume":"205","author":"Sibai","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1097\/AOG.0b013e3181fe02ec","article-title":"Association of Anticardiolipin Antibodies with Preeclampsia: A systematic review and meta-analysis","volume":"116","author":"Prado","year":"2010","journal-title":"Obstet. Gynecol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1161\/01.HYP.0000188979.74172.4d","article-title":"Thrombophilia Is Significantly Associated with Severe Preeclampsia: Results of a large-scale, case-controlled study","volume":"46","author":"Mello","year":"2005","journal-title":"Hypertension"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/j.1600-0412.2010.01030.x","article-title":"Placental abruption: Epidemiology, risk factors and consequences","volume":"90","author":"Tikkanen","year":"2011","journal-title":"Acta Obstet. Gynecol. Scand."},{"key":"ref_34","first-page":"785","article-title":"Thrombophilic mutations are a main risk factor for placental abruption","volume":"88","author":"Facchinetti","year":"2003","journal-title":"Haematologica"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1182\/blood.V112.11.1819.1819","article-title":"The Association between Antiphospholipid Antibodies and Adverse Pregnancy Outcomes: A Metaanalysis","volume":"112","author":"Carrier","year":"2008","journal-title":"Blood"},{"key":"ref_36","first-page":"572","article-title":"Risk of developing antiphospholipid antibodies following viral infection: A systematic review and meta-analysis","volume":"27","author":"Talathi","year":"2017","journal-title":"Lupus"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.5152\/eurjrheum.2015.0085","article-title":"The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus","volume":"3","author":"Unlu","year":"2016","journal-title":"Eur. J. Rheumatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1055\/s-0037-1613259","article-title":"Laboratory diagnosis of lupus anticoagulants for patients on oral anticoagulant treatment. Performance of dilute Russell viper venom test and silica clotting time in comparison with Staclot LA","volume":"88","author":"Tripodi","year":"2002","journal-title":"Thromb. Haemost."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1111\/jth.14846","article-title":"Lupus anticoagulant detection in anticoagulated patients. Guidance from the Scientific and Standardization Committee for lupus anticoagulant\/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Tripodi","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/ijlh.12138","article-title":"Frequent False-positive results of lupus anticoagulant tests in plasmas of patients receiving the new oral anticoagulants and enoxaparin","volume":"36","author":"Martinuzzo","year":"2013","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1160\/TH17-03-0204","article-title":"Effects of direct oral anticoagulants on lupus anticoagulant assays in a real-life setting","volume":"117","author":"Antovic","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e12676","DOI":"10.1002\/rth2.12676","article-title":"Lupus anticoagulant testing during anticoagulation, including direct oral anticoagulants","volume":"6","author":"Favaloro","year":"2022","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1097\/AOG.0000000000000230","article-title":"Postpartum Venous Thromboembolism: Incidence and risk factors","volume":"123","author":"Tepper","year":"2014","journal-title":"Obstet. Gynecol."},{"key":"ref_44","unstructured":"(2018). ACOG Practice Bulletin No. 196: Thromboembolism in Pregnancy. Obstet. Gynecol., 132, e1\u2013e17."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e2254765","DOI":"10.1001\/jamanetworkopen.2022.54765","article-title":"Patterns of Postpartum Primary Care Follow-up and Diabetes-Related Care after Diagnosis of Gestational Diabetes","volume":"6","author":"Dalmacy","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/art.39668","article-title":"Brief Report: Changes in Antiphospholipid Antibody Titers During Pregnancy: Effects on Pregnancy Outcomes","volume":"68","author":"Yelnik","year":"2016","journal-title":"Arthritis Rheumatol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/13\/4516\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:07:00Z","timestamp":1760126820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/13\/4516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,6]]},"references-count":46,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["jcm12134516"],"URL":"https:\/\/doi.org\/10.3390\/jcm12134516","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,7,6]]}}}